Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study

Trial Profile

Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs APD 209 (Primary)
  • Indications Adenovirus infections; Infectious keratoconjunctivitis; Keratoconjunctivitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Adenovir Pharma
  • Most Recent Events

    • 27 Apr 2016 According to Adenovir media release, results are expected in the second quarter 2016.
    • 27 Apr 2016 Status changed from recruiting to completed, as reported by Adenovir media release.
    • 30 Apr 2015 Planned End Date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top